South Korea
· Delayed Price · Currency is KRW GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 74.10 billion. The enterprise value is 81.89 billion.
| Market Cap | 74.10B |
| Enterprise Value | 81.89B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 76.87 million shares outstanding. The number of shares has increased by 13.58% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 76.87M |
| Shares Change (YoY) | +13.58% |
| Shares Change (QoQ) | +2.17% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | n/a |
| Float | 47.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.73 |
| PB Ratio | 3.78 |
| P/TBV Ratio | 3.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -23.96 |
| EV / Sales | 3.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.63 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.75.
| Current Ratio | 1.53 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.16 |
| Interest Coverage | -3.02 |
Financial Efficiency
Return on equity (ROE) is -20.72% and return on invested capital (ROIC) is -4.90%.
| Return on Equity (ROE) | -20.72% |
| Return on Assets (ROA) | -3.90% |
| Return on Capital (ROIC) | -4.90% |
| Revenue Per Employee | 922.23M |
| Profits Per Employee | -126.58M |
| Employee Count | 27 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.35% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -9.35% |
| 50-Day Moving Average | 1,039.90 |
| 200-Day Moving Average | 1,139.42 |
| Relative Strength Index (RSI) | 38.03 |
| Average Volume (20 Days) | 469,963 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 24.90 billion and -3.42 billion in losses. Loss per share was -48.41.
| Revenue | 24.90B |
| Gross Profit | 9.13B |
| Operating Income | -2.53B |
| Pretax Income | -3.45B |
| Net Income | -3.42B |
| EBITDA | -758.50M |
| EBIT | -2.53B |
| Loss Per Share | -48.41 |
Balance Sheet
The company has 6.87 billion in cash and 14.66 billion in debt, giving a net cash position of -7.79 billion or -101.32 per share.
| Cash & Cash Equivalents | 6.87B |
| Total Debt | 14.66B |
| Net Cash | -7.79B |
| Net Cash Per Share | -101.32 |
| Equity (Book Value) | 19.58B |
| Book Value Per Share | 254.75 |
| Working Capital | 6.08B |
Cash Flow
In the last 12 months, operating cash flow was -4.23 billion and capital expenditures -415.74 million, giving a free cash flow of -4.64 billion.
| Operating Cash Flow | -4.23B |
| Capital Expenditures | -415.74M |
| Free Cash Flow | -4.64B |
| FCF Per Share | -60.42 |
Margins
Gross margin is 36.65%, with operating and profit margins of -10.16% and -13.73%.
| Gross Margin | 36.65% |
| Operating Margin | -10.16% |
| Pretax Margin | -13.85% |
| Profit Margin | -13.73% |
| EBITDA Margin | -3.05% |
| EBIT Margin | -10.16% |
| FCF Margin | n/a |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.58% |
| Shareholder Yield | -13.58% |
| Earnings Yield | -5.02% |
| FCF Yield | -6.27% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GL Pharm Tech has an Altman Z-Score of 2.14. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | n/a |